Research programme: anti-infectives - BioDiem
Alternative Names: BDM-I; BMD I; OPAL-I; OPAL-TLatest Information Update: 06 Jan 2023
At a glance
- Originator Unknown
- Developer BioDiem; QIMR Berghofer Medical Research Institute; United States Army Medical Research Institute of Infectious Diseases
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Bacterial infections; Schistosomiasis
- Research Mycoses
Most Recent Events
- 29 Dec 2022 Early research in Bacterial infections in Australia (Parenteral) (Biodiem website, December 2022)
- 29 Dec 2022 Early research in Mycoses in Australia, USA (unspecified route) (Biodiem website, December 2022)
- 29 Dec 2022 Preclinical trials in Bacterial infections in USA (unspecified route) (Biodiem website, December 2022)